Fielmann (FRA:FIE) Rating Reiterated by DZ Bank

Share on StockTwits

DZ Bank restated their buy rating on shares of Fielmann (FRA:FIE) in a report published on Friday morning, Borsen Zeitung reports.

Several other research firms have also recently weighed in on FIE. Deutsche Bank set a €62.00 ($72.09) price target on Fielmann and gave the stock a neutral rating in a research note on Friday, August 30th. Kepler Capital Markets set a €60.50 ($70.35) price objective on Fielmann and gave the company a sell rating in a research report on Tuesday, September 17th. HSBC set a €75.00 ($87.21) price objective on Fielmann and gave the company a buy rating in a research report on Tuesday, September 3rd. Hauck & Aufhaeuser set a €41.00 ($47.67) price objective on Fielmann and gave the company a sell rating in a research report on Friday, August 30th. Finally, Independent Research set a €72.00 ($83.72) price objective on Fielmann and gave the company a neutral rating in a research report on Thursday, August 29th. Two analysts have rated the stock with a sell rating, six have given a hold rating and four have assigned a buy rating to the stock. The stock currently has an average rating of Hold and an average price target of €62.05 ($72.15).

FIE stock opened at €68.10 ($79.19) on Friday. Fielmann has a 1-year low of €65.50 ($76.16) and a 1-year high of €77.50 ($90.12). The business has a fifty day moving average price of €66.29 and a 200-day moving average price of €63.49.

About Fielmann

Fielmann Aktiengesellschaft invests in and operates optical and hearing aid businesses in Germany, Switzerland, Austria, and internationally. The company designs, manufactures, distributes, and retails visual aids and other optical products, including glasses, frames, lenses, sunglasses, contact lenses, and related articles and accessories, as well as hearing aids and accessories.

See Also: Compound Interest

Analyst Recommendations for Fielmann (FRA:FIE)

Receive News & Ratings for Fielmann Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fielmann and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.